title: Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression.
abstract: Antidepressants have an antiproliferative effect in some cell lines. Depression may be associated with activation of some pro-inflammatory cytokines. Therefore, we evaluated the ex-vivo immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) in T cells. We found that the SSRIs, paroxetine and sertraline decreased T-cell viability with IC50 around 10 microM. The inhibition obtained with exposure to the SSRIs was more pronounced than that achieved with dexamethasone. Moreover, these SSRIs inhibit the secretion of the TH1 factor-tumor necrosis factor(TNF)alpha from the cells. On the molecular level, the SSRIs suppressed signal transducer and activator of transcription 3 (Stat3) and cyclooxygenase(Cox)2 protein expression. The inhibitory effects were accompanied by alterations in gene expression as assessed in the gene array. These findings reveal an immunomodulatory effect of the SSRIs paroxetine and sertraline in human T cells. The clinical implications of our findings merit further investigation.
authors.affiliation: Laboratory of Biological Psychiatry, Felsenstein Medical Research Center and Sackler Faculty of Medicine, Tel Aviv University, Israel. michalt@post.tau.ac.il
authors.forename: Michal
authors.initials: M
authors.lastname: Taler
authors.forename: Irit
authors.initials: I
authors.lastname: Gil-Ad
authors.forename: Liat
authors.initials: L
authors.lastname: Lomnitski
authors.forename: Inna
authors.initials: I
authors.lastname: Korov
authors.forename: Ehud
authors.initials: E
authors.lastname: Baharav
authors.forename: Meytal
authors.initials: M
authors.lastname: Bar
authors.forename: Amichay
authors.initials: A
authors.lastname: Zolokov
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D015870:Gene Expression / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D017374:Paroxetine / Q000494:pharmacology; D050796:STAT3 Transcription Factor / Q000235:genetics / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D020280:Sertraline / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects*
chemical_list: D000893:Anti-Inflammatory Agents; D000928:Antidepressive Agents; D051546:Cyclooxygenase 2; D016207:Cytokines; D003907:Dexamethasone; D017374:Paroxetine; D050796:STAT3 Transcription Factor; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; C494086:STAT3 protein, human; C496540:PTGS2 protein, human